[Comment] Is PORTEC-4a the tipping point in endometrial cancer management? The PORTEC-4a trial1 provides, to the best of our knowledge, the first prospective, randomised evidence that a molecular integrated risk profile can safely guide adjuvant therapy decisions in high-intermediate risk endometrial cancer, reinforcing the rationale for incorporating molecular classification into clinical practice. According to Anne Sophie V M van den Heerik and colleagues’ findings in the Lancet Oncology,2 a refined… The Lancet Oncology December 23, 2025 Original source
[Editorial] Cancer consequences of the HIV funding crisis Reductions in development assistance funding by previous major donors—the USA, the UK, France, and Germany—have led to substantial challenges to global HIV control in 2025. Against this stark backdrop, World AIDS Day 2025 was commemorated globally on Dec 1, 2025. UNAIDS released a report ahead of the day detailing the impact of the unprecedented changing international aid landscape on global… The Lancet Oncology December 23, 2025 Original source
A Phase II, Randomized, open-label study to evaluate low-dose Pembrolizumab plus Chemotherapy vs Chemotherapy as Neoadjuvant Therapy for localized Triple Negative Breast Cancer (TNBC). [PLANeT Trial – Pembrolizumab Low Dose in Addition to NACT in TNBC] Addition of pembrolizumab to neoadjuvant chemotherapy (NACT) is a standard of care treatment in non-metastatic triple negative breast cancer (TNBC). Trials employing reduced doses of immune checkpoint inhibitors have yielded encouraging activity in several tumor types. Whether low-dose pembrolizumab enhances pathological complete response when added to NACT in triple-negative breast cancer remains uncertain. Annals of Oncology December 22, 2025 Original source
Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial. Anti-epidermal growth factor receptor (EGFR) drug rechallenge could be of therapeutic value in a subgroup of refractory metastatic colorectal cancer (mCRC). Annals of Oncology December 22, 2025 Original source
Pelvic lymph node dissection in prostate cancer, still no level 1 evidence of oncological benefit. Time to consider surveillance of negative pelvic lymph nodes on PSMA PET scan staging <p>Prostate Cancer and Prostatic Diseases, Published online: 20 December 2025; <a href="https://www.nature.com/articles/s41391-025-01065-5">doi:10.1038/s41391-025-01065-5</a></p>Pelvic lymph node dissection in prostate cancer, still no level 1 evidence of oncological benefit. Time to consider surveillance of negative pelvic lymph nodes on PSMA PET scan staging Prostate Cancer Journal December 20, 2025 Original source
A tale of two trials: TAILORx and PlanB. Letter to the Editor regarding “Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/ HER2-negative breast cancer” by Chen et al. Use of effective but relatively toxic anthracyclines remains one of the most controversial issues in the treatment of early breast cancer (eBC). A recent meta-analysis showed a significantly better invasive (iDFS) and distant disease-free survival after concurrent anthracycline-taxane vs. taxane-based chemotherapy in HR-positive/HER2-negative eBC.1 Recently, Chen and colleagues demonstrated that patients with node-negative, HR-positive/HER2-negative early breast cancer (eBC), and high… Annals of Oncology December 20, 2025 Original source
Selective expansion of T-cell receptor engineered T cells with increased stem-like phenotypes using neoantigen stimulation Background <p>Adoptive transfer of T-cell receptor-engineered T cells (TCR-T cells) has shown promising efficacy in solid tumor treatment, but achieving clinical benefit typically requires infusion of tens of billions of cells. The commonly used rapid expansion protocol (REP), based on the CD3-agonistic OKT3 antibody and irradiated allogeneic feeder cells, exponentially expands tumor-infiltrating lymphocytes (TILs). However, the effect of REP on… Journal for ImmunoTherapy of Cancer December 20, 2025 Original source
CD300e is a driver of the immunosuppressive tumor microenvironment and colorectal cancer progression via macrophage reprogramming Background <p>Colorectal cancer (CRC) progression is shaped by the tumor microenvironment, particularly tumor-associated macrophages (TAMs), which often adopt immunosuppressive functions. CD300e, a myeloid receptor involved in immune regulation, has an uncharacterized role in CRC.</p> Methods <p>Functional studies were conducted in azoxymethane/dextran sodium sulfate and MC38 murine CRC models using CD300e systemic and myeloid-specific CD300e knockout mice, and adoptive transfer experiments… Journal for ImmunoTherapy of Cancer December 20, 2025 Original source
PINK1 dysfunction in hepatocellular carcinoma fosters immune evasion and disease progression by promoting neutrophil infiltration Background <p>Despite breakthroughs in immune checkpoint blockade (ICB) for advanced hepatocellular carcinoma (HCC), tumor immune evasion remains a major limitation to immunotherapy efficacy. PTEN-induced putative kinase 1 (PINK1) has highlighted roles in immune system regulation and tumor progression, but its specific role in HCC and impact on ICB response remains unclear. This study aimed to elucidate how PINK1 dysfunction enables… Journal for ImmunoTherapy of Cancer December 20, 2025 Original source
Autologous profiling reveals inter-patient heterogeneity in V{delta}2+{gamma}{delta}TIL responses to glioblastoma driven by extracellular matrix-BTN3A axis Background <p>The effectiveness of immunotherapies against glioblastoma (GB) remains limited. A major obstacle in advancing new strategies is the reliance on non-autologous systems, which do not accurately mimic the true extent of inter-patient heterogeneity in both immune responses and tumor susceptibility. This often leads to misleading conclusions about therapeutic efficacy and targetability.</p> Methods <p>In this study, we addressed this critical… Journal for ImmunoTherapy of Cancer December 20, 2025 Original source
Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1 Background <p>Neutralization of interferon (IFN)- abrogates the efficacy of anti-programmed death-ligand 1 (PD-(L)1) checkpoint inhibitors. Most epithelial cells do not constitutively express major histocompatibility complex (MHC) class II but can be induced to do so by IFN-. Inducible tumor-specific MHC class II (tsMHC-II) underlies responsiveness to anti-PD-(L)1. Retrospective studies show that tsMHC-II positivity associates with improved outcomes in patients treated… Journal for ImmunoTherapy of Cancer December 20, 2025 Original source
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial Adding the pan-AKT inhibitor capivasertib to first-line paclitaxel in metastatic triple-negative breast cancer (TNBC) led to significantly longer progression-free survival (PFS) and overall survival (OS) versus placebo–paclitaxel in the phase II PAKT trial. CAPItello-290 was designed to further assess capivasertib–paclitaxel, including in patients with PIK3CA/AKT1/PTEN-altered tumours. Annals of Oncology December 19, 2025 Original source
The Achilles heel of precision AKT-targeted therapies in advanced prostate cancer: therapeutic promise constrained by the test The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway is frequently activated in many cancers, including prostate cancer where this is often following loss of phosphatase and tensin homolog (PTEN). The CAPItello-281 trial is the first phase III trial to evaluate AKT inhibition added at start of androgen deprivation therapy for metastatic prostate cancer, specifically in combination with abiraterone acetate and… Annals of Oncology December 19, 2025 Original source
Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up† Diagnosis of prostate cancer is primarily based on PSA testing, digital rectal examination (DRE) and imaging to select men for prostate biopsy. Moderately elevated PSA concentrations (3-10 ng/ml) have limited specificity for detection, indicating the need for more accurate biomarkers. PSA-density (PSA-D), derived from PSA level divided by prostate volume, can add value in predicting clinically significant disease.1 Several blood… Annals of Oncology December 18, 2025 Original source
Assessing How Obesity Affects the Risk of Endometrial Cancer . <br /> Nutrition and Cancer Journal December 17, 2025 Original source
Twenty-Five Years of Progress in Cancer <p>As we close out the first quarter of the twenty-first century, it isn’t hard to notice how much the world has changed since the year 2000. Smartphones. Social media. Artificial intelligence.   But how much has cancer care changed? A lot. Possibly more than you think. Treatment for many cancers now include many options beyond chemotherapy, ... <a class="read-more" href="https://blog.dana-farber.org/insight/2025/12/twenty-five-years-of-progress-in-cancer/" title="Twenty-Five… Dana-Farber Cancer Institute December 17, 2025 Original source
Germline alterations in patients with lung cancer Similar distribution of P/LP potential germline alterations in lung cancer subtypes from distinct populations by smoking status suggests increased next-generation germline sequencing may improve risk assessment. Annals of Oncology December 16, 2025 Original source
Commentary: Ultrasound Measurements of Skeletal Muscle Predict Chemotherapy Toxicity in Non-Small Cell Lung Cancer . <br /> Nutrition and Cancer Journal December 16, 2025 Original source